

Corresponding author(s):	C. Theresa Vincent and Scott C. Blanchard
Last undated by author(s).	Apr E 2010

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

Statistics		
For all statistical analys	ses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.	
n/a Confirmed		
☐ ☐ The exact san	nple size (n) for each experimental group/condition, given as a discrete number and unit of measurement	
A statement	on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly	
The statistica Only common t	I test(s) used AND whether they are one- or two-sided tests should be described solely by name; describe more complex techniques in the Methods section.	
A description	of all covariates tested	
A description	of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons	
A full descript AND variation	tion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) in (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)	
For null hypor	thesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted s exact values whenever suitable.	
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings		
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes		
Estimates of o	effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated	
,	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.	
Software and o	code	
Policy information abo	ut <u>availability of computer code</u>	
Data collection	N/A	
Data analysis	N/A	
	tom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.	
Data		
Accession codes, urA list of figures that	out <u>availability of data</u> include a <u>data availability statement</u> . This statement should provide the following information, where applicable: nique identifiers, or web links for publicly available datasets have associated raw data v restrictions on data availability	
All data will be made ava BioProject: PRJNA531030	ailable upon request from the authors. The RNA sequencing data presented are available through the Sequence Read Archive 0.	
Field-spec	ific reporting	
Please select the one k	pelow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.	
X Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences	

Life sciences study design

	· · · · · · · · · · · · · · · · · · ·	
All studies must disclose on	these points even when the disclosure is negative.	
	size was chosen by an estimate of the number of animals needed to detect a 30% difference in the primary endpoints (tumor growth metastatic colonization), based on the experience of the authors.	
Data exclusions No data	data was excluded from the analysis	
Replication Each ex	periment was performed in three biological replicates.	
Randomization No rand	omization was used	
Blinding The inve	estigator performing animal experiments was aware of which therapy was administered to each group.	
We require information from a	n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging rganisms	
Antibodies		
Antibodies used	See Table 1.	
Validation	All antibodies used in this study are commercially available and validated.	
Eukaryotic cell lin	es es	
Policy information about <u>ce</u>	<u>Il lines</u>	
Cell line source(s)	Methods; ATCC, RIKEN BRC and collaborators	
Authentication	All cell lines were purchased from ATCC, RIKEN BRC or verified by collaborators	
Mycoplasma contaminati	On Cells were routinely tested for mycoplasma	
Commonly misidentified (See ICLAC register)	ines N/A	
Animals and othe	r organisms	
Policy information about <u>st</u>	udies involving animals; ARRIVE guidelines recommended for reporting animal research	
Laboratory animals	Methods. MMTV-PyMT (FVB/N), C57 BL/6	
Wild animals	N/A	
Field-collected samples	N/A	
Ethics oversight	Methods; (Stockholm Norra, license# N96/11 and Lund, license# M142/13), #0709-666A, #1184203	

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants

Policy information about <u>studies involving human research participants</u>		
Population characteristics	N/A	
Recruitment	N/A	
Ethics oversight	Methods: The "Ethics Committee at the Karolinska Institutet" Stockholm and the "Stockholm Medical Biobank"	

Note that full information on the approval of the study protocol must also be provided in the manuscript.